Oligomerix is an early-stage biotechnology company focused on discovering and developing novel, small-molecule tau oligomer inhibitors of self-association for Alzheimer’s disease (AD) and related neurodegenerative diseases with tau pathology. Oligomerix’ drug discovery platform has identified a pipeline of novel, central nervous system (CNS) small molecule lead compounds designed to inhibit tau oligomer formation at the beginning of the tau cascade. The company’s lead program targeting AD has initiated IND-enabling studies. The NYC based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine and has received considerable support from the National Institute of Health (NIH). Oligomerix is seeking strategic partners to support the acceleration and advancement of these important programs. For more information about Oligomerix, please visit www.Oligomerix.com
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2006
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
Tau inhibitor of self-association
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
